



*In partnership with the
American Liver Foundation, Conn. Chapter,
the Yale Fatty Liver Disease Program
is proud to present:*

Evaluation and Management of Fatty Liver Disease and Obesity: Clinical Update

*Come learn about the latest in clinical management and advances
in the management of fatty liver disease and patients with obesity*

**Saturday, October 5 from 11 a.m. - 3 p.m.
Mystic Hilton, Mystic, CT**

**Course organizer: Albert Do, MD, MPH, clinical director,
Yale Fatty Liver Disease Program**

There is no corporate support for this activity.

Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, and staff, and local GI physicians. **Designation Statement:** The Yale School of Medicine designates this live activity for 3.5 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** The Yale Fatty Liver Disease is a nascent program at Yale which focuses on advancing knowledge and care of fatty liver disease including nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease in the United States. Currently, there are no effective and widely-available treatments for NAFLD, other than weight loss as it is a disease of obesity. Thus, the Yale Fatty Liver disease program additionally seeks to incorporate medical and endoscopic weight loss in to the care of patients with NAFLD. Further education of non-hepatology providers is needed to improve evaluation and management of both NAFLD and obesity. **Objectives:** Identify patient characteristics and diagnostic test results suggesting of both alcoholic and nonalcoholic fatty liver disease (NAFLD). Appreciate the spectrum of disease of NAFLD, which may range from

nonalcoholic fatty liver to nonalcoholic steatohepatitis with or without fibrosis. Recall the pathophysiology, epidemiology, and natural history of NAFLD. Appreciate the role of NAFLD as a disease of obesity and its relationship with other metabolic diseases. Recognize the insidious nature of NAFLD even in the absence of normal aminotransferases. Perform diagnostic workup for NAFLD including ruling out alternative chronic liver diseases and fibrosis staging tests. Understand basic principles of obesity medicine including motivational interviewing, medication review, and medical management of obesity. **Faculty Disclosures:** Disclosures on file. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**

**Free to attend but RSVP is required.
Lunch will be provided.**

For more information and to RSVP, contact Antonio Trombino
at antonio.trombino@westerlyhospital.org or email liver.health@yale.edu



Your Liver. Your Life.